Westfield Capital Management
EIDX

Westfield Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Westfield Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-93,422
Closed -$12.3M – 296
2020
Q4 		$12.3M Sell
93,422
-145,760
-61% -$12.9M 0.07% 188
2020
Q3 		$12.1M Buy
+239,182
New +$10.8M 0.08% 183

Westfield Capital Management's EIDX Position: Q1 2021 in Review

Westfield Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 93,422 shares — an estimated $12.3M sold.

Westfield Capital Management first reported a position in EIDX in Q3 2020 and held it in 2 quarters. The position peaked at $12.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Westfield Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Westfield Capital Management sold 93,422 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $12.3M.
  • Westfield Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Westfield Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $12.3M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Westfield Capital Management's 13F filing for Q1 2021, filed 14 May 2021.